NLRP3 and Opportunistic infection: This is of particular relevance when considering that in a targeted anti-NLRP3 therapy, other pathogen-recognizing inflammasomes can be engaged to produce IL-1β, thus reducing the risk of immune suppression and opportunistic infections.